LncRNAs in hepatocellular carcinoma: molecular drivers and emerging therapeutic targets

Abstract

Hepatocellular carcinoma (HCC) functions as a major cancer-related death factor around the world. Research indicates that long non-coding RNAs (lncRNAs) play essential roles during HCC onset and development because they belong to the novel RNA subclass that extends beyond 200 nucleotides without protein-coding capability. LncRNAs regulate the expression of downstream target genes and cancer-related signaling pathways, thereby promoting the proliferation, migration, invasion, autophagy, and apoptosis of tumor cells. The study of lncRNA function has been substantially facilitated by the emergence of lncRNA-specific microarrays and the increased accessibility of next-generation sequencing technologies. The function of lncRNAs can be predicted using computational and molecular methodologies. LncRNAs have the potential to function as repressors, scaffolds, regulators of super-enhancers, or molecular decoys. Proliferation, invasion, survival, DNA damage response (DDR), and chromatin dynamics can all be influenced by lncRNAs. Additionally, they can affect stemness/differentiation. The recurrence of tumors may be facilitated by the aberrant expression of these transcripts, which may result in therapy resistance. LncRNAs have the potential to function as innovative prognostic or theranostic biomarkers in HCC and other malignancies. In addition, RNA-based therapeutics may be implemented to target lncRNAs as a novel treatment approach for primary or recurrent HCC. In this review, we investigate the functions of lncRNAs in the pathophysiology of HCC and suggest their potential for novel therapeutic application in the treatment of HCC.

References

[1] Hammad R, Eldosoky MA, Elmadbouly AA, Aglan RB, AbdelHamid SG, Zaky S, et al. Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023; 149: 15349-64.

[2] Li S, Peng M, Tan S, Oyang L, Lin J, Xia L, et al. The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming. Cancer Cell Int. 2024; 24: 37.

[3] Abaza T, El-Aziz MKA, Daniel KA, Karousi P, Papatsirou M, Fahmy SA, et al. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy. Int J Mol Sci. 2023; 24: 16484.

[4] Zhang W, Zeng B, Yang M, Yang H, Wang J, Deng Y, et al. ncRNAVar: A Manually Curated Database for Identification of Noncoding RNA Variants Associated with Human Diseases. J Mol Biol. 2021; 433: 166727.

[5] Li H, Hu X, Wang L, Gu X, Chen S, Tang Y, et al. The Expression of Ferroptosis-Related Genes in Hepatocellular Carcinoma and Their Relationships With Prognosis. J Hepatocell Carcinoma. 2025; 12: 629-48.

[6] Johnson PJ, Kalyuzhnyy A, Boswell E, Toyoda H. Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management. BJC Rep. 2024; 2: 39.

[7] Shah M, Sarkar D. HCC-Related lncRNAs: Roles and Mechanisms. Int J Mol Sci. 2024; 25: 597.

[8] Wong C, Wei L, Law C, Ho DW, Tsang FH, Au SL, et al. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology. 2016; 63: 474-87.

[9] Long Y, Hwang T, Gooding AR, Goodrich KJ, Rinn JL, Cech TR. RNA is essential for PRC2 chromatin occupancy and function in human pluripotent stem cells. Nat Genet. 2020; 52: 931-8.

[10] Huang M, Chen W, Qi F, Sun M, Xu T, Ma P, et al. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Mol Cancer. 2015; 14: 165.

[11] Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology. 2014; 59: 911-23.

[12] Yi T, Wang T, Shi Y, Peng X, Tang S, Zhong L, et al. Long noncoding RNA 91H overexpression contributes to the growth and metastasis of HCC by epigenetically positively regulating IGF2 expression. Liver Int. 2020; 40: 456-67.

[13] Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, et al. lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. Cell Death Dis. 2018; 9: 487.

[14] Zhang L, Niu H, Ma J, Yuan B, Chen Y, Zhuang Y, et al. The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma. Mol Cancer. 2019; 18: 120.

[15] Wang Y, Zhu P, Luo J, Wang J, Liu Z, Wu W, et al. LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling. EMBO J. 2019; 38: e101110.

[16] Boque-Sastre R, Soler M, Oliveira-Mateos C, Portela A, Moutinho C, Sayols S, et al. Head-to-head antisense transcription and R-loop formation promotes transcriptional activation. Proc Natl Acad Sci U S A. 2015; 112: 5785-90.

[17] Li Y, Syed J, Sugiyama H. RNA-DNA Triplex Formation by Long Noncoding RNAs. Cell Chem Biol. 2016; 23: 1325-33.

[18] Postepska-Igielska A, Giwojna A, Gasri-Plotnitsky L, Schmitt N, Dold A, Ginsberg D, et al. LncRNA Khps1 Regulates Expression of the Proto-oncogene SPHK1 via Triplex-Mediated Changes in Chromatin Structure. Mol Cell. 2015; 60: 626-36.

[19] Xiang J, Yin Q, Chen T, Zhang Y, Zhang X, Wu Z, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014; 24: 513-31.

[20] Rashid F, Shah A, Shan G. Long Non-coding RNAs in the Cytoplasm. Genomics Proteomics Bioinformatics. 2016; 14: 73-80.

[21] Yuan S, Wang J, Yang F, Tao Q, Zhang J, Wang L, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2016; 63: 499-511.

[22] Liu J, Xu R, Mai S, Ma Y, Zhang M, Cao P, et al. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. Theranostics. 2020; 10: 7527-44.

[23] Qin G, Tu X, Li H, Cao P, Chen X, Song J, et al. Long Noncoding RNA p53-Stabilizing and Activating RNA Promotes p53 Signaling by Inhibiting Heterogeneous Nuclear Ribonucleoprotein K deSUMOylation and Suppresses Hepatocellular Carcinoma. Hepatology. 2020; 71: 112-29.

[24] Xu J, Lu Y, Liu Q, Xia A, Zhao J, Xu X, et al. Long noncoding RNA GMAN promotes hepatocellular carcinoma progression by interacting with eIF4B. Cancer Lett. 2020; 473: 1-12.

[25] Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, et al. Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int J Mol Sci. 2019; 20: 5573.

[26] Keihani S, Kluever V, Fornasiero EF. Brain Long Noncoding RNAs: Multitask Regulators of Neuronal Differentiation and Function. Molecules. 2021; 26: 3951.

[27] Lin X, Spindler TJ, de Souza Fonseca MA, Corona RI, Seo J, Dezem FS, et al. Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer. iScience. 2019; 17: 242-55.

[28] Peng L, Jiang B, Yuan X, Qiu Y, Peng J, Huang Y, et al. Super-Enhancer-Associated Long Noncoding RNA HCCL5 Is Activated by ZEB1 and Promotes the Malignancy of Hepatocellular Carcinoma. Cancer Res. 2019; 79: 572-84.

[29] Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. 1991; 349: 38-44.

[30] Wei J, Huang K, Yang C, Kang C. Non-coding RNAs as regulators in epigenetics (Review). Oncol Rep. 2017; 37: 3-9.

[31] Solhi R, Pourhamzeh M, Zarrabi A, Hassan M, Mirzaei H, Vosough M. Novel biomarkers for monitoring and management of hepatocellular carcinoma. Cancer Cell Int. 2024; 24: 428.

[32] Duan H, Li X, Chen Y, Wang Y, Li Z. LncRNA RHPN1-AS1 promoted cell proliferation, invasion and migration in cervical cancer via the modulation of miR-299-3p/FGF2 axis. Life Sci. 2019; 239: 116856.

[33] Zhang M, Song Y, Yu L. LncRNA PTCSC3 suppressed cervical carcinoma cell invasion and proliferation via regulating miR-574-5p. Am J Transl Res. 2019; 11: 7186-94.

[34] Li S, Hao J, Hong Y, Mai J, Huang W. Long Non-Coding RNA NEAT1 Promotes the Proliferation, Migration, and Metastasis of Human Breast-Cancer Cells by Inhibiting miR-146b-5p Expression. Cancer Manag Res. 2020; 12: 6091-101.

[35] Zhuang S, Cai Y, Liu H, Qin Y, Wen J. LncRNA NEAT1/miR-185-5p/IGF2 axis regulates the invasion and migration of colon cancer. Mol Genet Genomic Med. 2020; 8: e1125.

[36] Yan D, Liu W, Liu Y, Luo M. LINC00261 suppresses human colon cancer progression via sponging miR-324-3p and inactivating the Wnt/β-catenin pathway. J Cell Physiol. 2019; 234: 22648-56.

[37] Liu J, Zhao S, Jiang Q, Qu Y, Huang X, Du J, et al. Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway. Int J Biol Sci. 2020; 16: 1989-2000.

[38] Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct Target Ther. 2024; 9: 192.

[39] Wang X, Li L, Zhao K, Lin Q, Li H, Xue X, et al. A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth. Cell Death Differ. 2020; 27: 1431-46.

[40] Wang X, Wang Y, Li L, Xue X, Xie H, Shi H, et al. A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia. Oncogene. 2020; 39: 1860-74.

[41] Li T, Wu D, Liu Q, Wang D, Chen J, Zhao H, et al. Upregulation of long noncoding RNA RAB11B-AS1 promotes tumor metastasis and predicts poor prognosis in lung cancer. Ann Transl Med. 2020; 8: 582.

[42] Zhang Q, Li T, Wang Z, Kuang X, Shao N, Lin Y. lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway. J Cell Mol Med. 2020; 24: 8236-47.

[43] Hussen BM, Azimi T, Hidayat HJ, Taheri M, Ghafouri-Fard S. NF-KappaB interacting LncRNA: Review of its roles in neoplastic and non-neoplastic conditions. Biomed Pharmacother. 2021; 139: 111604.

[44] Ruan Z, Zhao D. Long intergenic noncoding RNA LINC00284 knockdown reduces angiogenesis in ovarian cancer cells via up-regulation of MEST through NF-κB1. FASEB J. 2019; 33: 12047-59.

[45] Li X, Zheng Z, Zhou W, Huang H, Zhou Y, Xu Q, et al. HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer. J Ovarian Res. 2024; 17: 124.

[46] Wu Y, Wang J, Zhao J, Su Y, Li X, Chen Z, et al. LTR retrotransposon-derived LncRNA LINC01446 promotes hepatocellular carcinoma progression and angiogenesis by regulating the SRPK2/SRSF1/VEGF axis. Cancer Lett. 2024; 598: 217088.

[47] Chakraborty S, Banerjee S. Combatting cellular immortality in cancers by targeting the shelterin protein complex. Biol Direct. 2024; 19: 120.

[48] Chebly A, Ropio J, Baldasseroni L, Prochazkova-Carlotti M, Idrissi Y, Ferrer J, et al. Telomeric Repeat-Containing RNA (TERRA): A Review of the Literature and First Assessment in Cutaneous T-Cell Lymphomas. Genes (Basel). 2022; 13: 539.

[49] Novakovic B, Napier CE, Vryer R, Dimitriadis E, Manuelpillai U, Sharkey A, et al. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta. Mol Hum Reprod. 2016; 22: 791-9.

[50] Manganelli M, Grossi I, Corsi J, DʼAgostino VG, Jurikova K, Cusanelli E, et al. Expression of Cellular and Extracellular TERRA, TERC and TERT in Hepatocellular Carcinoma. Int J Mol Sci. 2022; 23: 6183.

[51] Xu CL, Sang B, Liu GZ, Li JM, Zhang XD, Liu LX, et al. SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms. Nucleic Acids Res. 2020; 48: 3089-102.

[52] Lee HC, Kang D, Han N, Lee Y, Hwang HJ, Lee S, et al. A novel long noncoding RNA Linc-ASEN represses cellular senescence through multileveled reduction of p21 expression. Cell Death Differ. 2020; 27: 1844-61.

[53] Montero JJ, López de Silanes I, Graña O, Blasco MA. Telomeric RNAs are essential to maintain telomeres. Nat Commun. 2016; 7: 12534.

[54] Singh DK, Cong Z, Song YJ, Liu M, Chaudhary R, Liu D, et al. MANCR lncRNA Modulates Cell-Cycle Progression and Metastasis by Cis-Regulation of Nuclear Rho-GEF . Mol Cell Biol. 2024; 44: 372-90.

[55] Elguindy MM, Mendell JT. NORAD-induced Pumilio phase separation is required for genome stability. Nature. 2021; 595: 303-8.

[56] Elguindy MM, Kopp F, Goodarzi M, Rehfeld F, Thomas A, Chang T, et al. PUMILIO, but not RBMX, binding is required for regulation of genomic stability by noncoding RNA NORAD . Elife. 2019; 8: e48625.

[57] Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, et al. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020; 159: 2146-62.e33.

[58] Luo H, Xu C, Le W, Ge B, Wang T. lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. J Cell Biochem. 2019; 120: 13487-93.

[59] Zhang C, Wang W, Lin J, Xiao J, Tian Y. lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. Int Braz J Urol. 2019; 45: 549-59.

[60] Zhuang C, Ma Q, Zhuang C, Ye J, Zhang F, Gui Y. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. FASEB J. 2019; 33: 11045-59.

[61] Rui X, Xu Y, Huang Y, Ji L, Jiang X. lncRNA DLG1-AS1 Promotes Cell Proliferation by Competitively Binding with miR-107 and Up-Regulating ZHX1 Expression in Cervical Cancer. Cell Physiol Biochem. 2018; 49: 1792-803.

[62] Al-Hawari SIS, Jasim SA, Altalbawy FMA, Bansal P, Kaur H, Hjazi A, et al. An overview of lncRNA NEAT1 contribution in the pathogenesis of female cancers; from diagnosis to therapy resistance. Gene. 2025; 933: 148975.

[63] Li K, Ma Y, Tian Y, Xu X, Gao Y, He Y, et al. Silencing lncRNA SNHG6 suppresses proliferation and invasion of breast cancer cells through miR-26a/VASP axis. Pathol Res Pract. 2019; 215: 152575.

[64] Zhang J, Huang J, Chen W, Hu Z, Wang X. miR-143-3p Targets lncRNA PSMG3-AS1 to Inhibit the Proliferation of Hepatocellular Carcinoma Cells. Cancer Manag Res. 2020; 12: 6303-9.

[65] Wang Y, Jiang D, Hu S, Zhao L, Wang L, Yang M, et al. SATB2-AS1 Suppresses Colorectal Carcinoma Aggressiveness by Inhibiting SATB2-Dependent Snail Transcription and Epithelial-Mesenchymal Transition. Cancer Res. 2019; 79: 3542-56.

[66] Fonseca-Montaño MA, Vázquez-Santillán KI, Hidalgo-Miranda A. The current advances of lncRNAs in breast cancer immunobiology research. Front Immunol. 2023; 14: 1194300.

[67] Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018; 19: 1112-25.

[68] Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018; 118: 24-30.

[69] Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y, et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019; 21: 498-510.

[70] Wang Y, Liu J, Shi M, Chen F. LncRNA DGCR5 represses the development of hepatocellular carcinoma by targeting the miR-346/KLF14 axis. J Cell Physiol. 2018; 234: 572-80.

[71] Luan X, Wang Y. LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. J Gynecol Oncol. 2018; 29: e95.

[72] Deng S, Chen H, Ye Z, Deng S, Zhu S, Zeng Z, et al. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene. 2018; 37: 5811-28.

[73] Liang H, Yu T, Han Y, Jiang H, Wang C, You T, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 2018; 17: 119.

[74] Hussein MA, Valinezhad K, Adel E, Munirathinam G. MALAT-1 Is a Key Regulator of Epithelial-Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis. Cancers (Basel). 2024; 16: 234.

[75] Kumar D, Gurrapu S, Wang Y, Bae S, Pandey PR, Chen H, et al. LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells. Nat Cancer. 2024; 5: 262-82.

[76] Song Z, Zhang X, Lin Y, Wei Y, Liang S, Dong C. LINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2. J Cell Mol Med. 2019; 23: 7554-65.

[77] Sengupta P, Roy A, Roy L, Bose D, Halder S, Jana K, et al. Long non-coding intergenic RNA, LINC00273 induces cancer metastasis and stemness via miRNA sponging in triple negative breast cancer. Int J Biol Macromol. 2024; 274: 132730.

[78] Zhu Y, Ren J, Wu X, Zhang Y, Wang Y, Xu J, et al. lncRNA ENST00000422059 promotes cell proliferation and inhibits cell apoptosis in breast cancer by regulating the miR-145-5p/KLF5 axis. Acta Biochim Biophys Sin (Shanghai). 2023; 55: 1892-901.

[79] Sun M, Geng D, Li S, Chen Z, Zhao W. LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem. 2018; 399: 387-95.

[80] Wang T, Tang X, Liu Y. LncRNA-ATB promotes apoptosis of non-small cell lung cancer cells through MiR-200a/β-Catenin. J BUON. 2019; 24: 2280-6.

[81] Lian Z, Tian P, Ma S, Chang T, Liu R, Feng Q, et al. Long noncoding RNA MEG3 regulates cell proliferation and apoptosis by disrupting microRNA-9-5p-mediated inhibition of NDRG1 in prostate cancer. Aging (Albany NY). 2024; 16: 1938-51.

[82] Beltrán-Anaya FO, Romero-Córdoba S, Rebollar-Vega R, Arrieta O, Bautista-Piña V, Dominguez-Reyes C, et al. Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. Mol Oncol. 2019; 13: 909-27.

[83] Mahboobnia K, Beveridge DJ, Yeoh GC, Kabir TD, Leedman PJ. MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities. Int J Mol Sci. 2024; 25: 9393.

[84] Bekric D, Ocker M, Mayr C, Stintzing S, Ritter M, Kiesslich T, et al. Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers (Basel). 2022; 14: 1826.

[85] Lin X, Yang S. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma. Adv Clin Exp Med. 2022; 31: 1099-109.

[86] Chen H, Han Z, Su J, Song X, Ma Q, Lin Y, et al. Ferroptosis and hepatocellular carcinoma: the emerging role of lncRNAs. Front Immunol. 2024; 15: 1424954.

[87] Zhang J, Pan T, Lee J, Goldberg S, King SA, Tang E, et al. Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer. Cell Rep Med. 2025; 6: 101920.

[88] Liu Y, He X, Chen Y, Cao D. Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244. Mol Cell Biochem. 2020; 464: 39-50.

[89] Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long Noncoding RNA MALAT1 Regulates Cancer Glucose Metabolism by Enhancing mTOR-Mediated Translation of TCF7L2. Cancer Res. 2019; 79: 2480-93.

[90] Zhu Y, Liu Q, Liao M, Diao L, Wu T, Liao W, et al. Overexpression of lncRNA EPB41L4A-AS1 Induces Metabolic Reprogramming in Trophoblast Cells and Placenta Tissue of Miscarriage. Mol Ther Nucleic Acids. 2019; 18: 518-32.

[91] Zhang H, Xu H, Kurban E, Luo H. LncRNA SNHG14 promotes hepatocellular carcinoma progression via H3K27 acetylation activated PABPC1 by PTEN signaling. Cell Death Dis. 2020; 11: 646.

[92] Zhao L, Lou G, Li A, Liu Y. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR 375 sponging. Mol Med Rep. 2020; 22: 1449-57.

[93] Jen J, Tang Y, Lu Y, Lin C, Lai W, Wang Y. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer. 2017; 16: 104.

[94] Ervin E, French R, Chang C, Pauklin S. Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer. Semin Cancer Biol. 2022; 87: 48-83.

[95] Zhang Y, Fang Z, Guo X, Dong H, Zhou K, Huang Z, et al. lncRNA B4GALT1-AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity. J Cell Physiol. 2019; 234: 18524-34.

[96] Liu J, Lu C, Xiao M, Jiang F, Qu L, Ni R. Long non-coding RNA SNHG20 predicts a poor prognosis for HCC and promotes cell invasion by regulating the epithelial-to-mesenchymal transition. Biomed Pharmacother. 2017; 89: 857-63.

[97] Taiana E, Bandini C, Favasuli VK, Ronchetti D, Silvestris I, Puccio N, et al. Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. Haematologica. 2023; 108: 219-33.

[98] Taiana E, Ronchetti D, Todoerti K, Nobili L, Tassone P, Amodio N, et al. LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems? Noncoding RNA. 2020; 6: 26.

[99] de Silva HC, Lin MZ, Phillips L, Martin JL, Baxter RC. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cell Mol Life Sci. 2019; 76: 2015-30.

[100] Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, et al. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018; 32: 2250-62.

[101] Fan L, Huang X, Chen J, Zhang K, Gu Y, Sun J, et al. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. Mol Cancer Ther. 2020; 19: 1197-209.

[102] Liu K, Gao L, Ma X, Huang J, Chen J, Zeng L, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020; 19: 54.

[103] He Q, Guo P, Bo Z, Yu H, Yang J, Wang Y, et al. Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma. Cancer Cell Int. 2022; 22: 249.

[104] Xiao J, Lv Y, Jin F, Liu Y, Ma Y, Xiong Y, et al. LncRNA HANR Promotes Tumorigenesis and Increase of Chemoresistance in Hepatocellular Carcinoma. Cell Physiol Biochem. 2017; 43: 1926-38.

[105] Zhou Y, Zhu Y, Xie Y, Ma X. The Role of Long Non-coding RNAs in Immunotherapy Resistance. Front Oncol. 2019; 9: 1292.

[106] Fang Y, Zhang X, Huang H, Zeng Z. The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things. J Transl Med. 2023; 21: 369.

[107] Jiang W, Pan S, Chen X, Wang Z, Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 2021; 20: 116.

[108] Vecchio FD, Lee GH, Hawezi J, Bhome R, Pugh S, Sayan E, et al. Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk. Cancer Lett. 2018; 421: 94-102.

[109] Lampropoulou DI, Pliakou E, Aravantinos G, Filippou D, Gazouli M. The Role of Exosomal Non-Coding RNAs in Colorectal Cancer Drug Resistance. Int J Mol Sci. 2022; 23: 1473.

[110] Ding L, Ren J, Zhang D, Li Y, Huang X, Hu Q, et al. A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis. 2018; 39: 397-406.

[111] Zhu G, Wang S, Chen J, Wang Z, Liang X, Wang X, et al. Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. Mol Carcinog. 2017; 56: 2210-22.

[112] Yuan J, Yang F, Wang F, Ma J, Guo Y, Tao Q, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014; 25: 666-81.

[113] Hou Z, Xu X, Fu X, Zhou L, Liu S, Tan D. Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140. Am J Physiol Cell Physiol. 2020; 318: C649-63.

[114] Jiang R, Tang J, Chen Y, Deng L, Ji J, Xie Y, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017; 8: 15129.

[115] Peng L, Chen Y, Ou Q, Wang X, Tang N. LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma. Int Immunopharmacol. 2020; 89: 107071.

[116] Jiang P, Li X. Regulatory Mechanism of lncRNAs in M1/M2 Macrophages Polarization in the Diseases of Different Etiology. Front Immunol. 2022; 13: 835932.

[117] Yu Z, Zhao H, Feng X, Li H, Qiu C, Yi X, et al. Long Non-coding RNA FENDRR Acts as a miR-423-5p Sponge to Suppress the Treg-Mediated Immune Escape of Hepatocellular Carcinoma Cells. Mol Ther Nucleic Acids. 2019; 17: 516-29.

[118] Wang Y, Yang L, Dong X, Yang X, Zhang X, Liu Z, et al. Overexpression of NNT-AS1 Activates TGF- β Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. Biomed Res Int. 2020; 2020: 8216541.

[119] Xiong H, Ni Z, He J, Jiang S, Li X, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017; 36: 3528-40.

[120] Cai H, Zheng Y, Wen Z, Yang Y, Yang S, Zhang Q. LncRNA AIRN influences the proliferation and apoptosis of hepatocellular carcinoma cells by regulating STAT1 ubiquitination. Arch Pharm Res. 2021; 44: 414-26.

[121] Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020; 13: 5.

[122] Ma J, Qin C, Yuan Z, Liu S. LncRNA PAPAS promotes hepatocellular carcinoma by interacting with miR-188-5p. J Cell Biochem. 2019; 120: 13494-500.

[123] Li W, Ge J, Xie J, Yang J, Chen J, He T. LncRNA TUG1 Promotes Hepatocellular Carcinoma Migration and Invasion Via Targeting the miR-137/AKT2 Axis. Cancer Biother Radiopharm. 2021; 36: 850-62.

[124] Wang M, Fang D, Di M, Guan J, Wang G, Liu L, et al. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway. Int J Med Sci. 2020; 17: 1224-34.

[125] Liu S, Huttad L, He G, He W, Liu C, Cai D, et al. Long noncoding RNA HULC regulates the NF-κB pathway and represents a promising prognostic biomarker in liver cancer. Cancer Med. 2023; 12: 5124-36.

[126] Tang C, Yu H, Zheng Y, Feng W, Shen J. lncRNA TINCR Regulates Proliferation and Invasion of Hepatocellular Carcinoma Cells by Regulating the miR-375/ATG7 Axis. J Oncol. 2022; 2022: 8132403.

[127] Lyu P, Li F, Deng R, Wei Q, Lin B, Cheng L, et al. Lnc-PIK3R1, transcriptionally suppressed by YY1, inhibits hepatocellular carcinoma progression via the Lnc-PIK3R1/miR-1286/GSK3β axis. Biochim Biophys Acta Mol Basis Dis. 2024; 1870: 167233.

[128] Sun D, Guan C, Wang W, Hu Z, Zhao Y, Jiang X. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis. Microvasc Res. 2021; 134: 104120.

[129] Yuan Y, Ye J, Zhang X, Liu Z. LncRNA CASC2 Regulate Cell Proliferation and Invasion by Targeting miR-155/SOCS1 Axis in Hepatocellular Carcinoma. J Oncol. 2023; 2023: 8457112.

[130] Su C, Zhang H, Mo J, Liao Z, Zhang B, Zhu P. SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation. Clin Transl Med. 2024; 14: e1563.

[131] Wang S, Zhang Q, Wang Q, Shen Q, Chen X, Li Z, et al. NEAT1 paraspeckle promotes human hepatocellular carcinoma progression by strengthening IL-6/STAT3 signaling. Oncoimmunology. 2018; 7: e1503913.

[132] Chu D, Jin Y, Wang B, Jiao Y, Zhang C, Guo Z, et al. LncRNA HOTAIR Enhances Epithelial-to-mesenchymal Transition to Promote the Migration and Invasion of Liver Cancer by Regulating NUAK1 via Epigenetic Inhibition miR-145-5p Expression. J Cancer. 2023; 14: 2329-43.

[133] Peng N, He J, Li J, Huang H, Huang W, Liao Y, et al. Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int. 2020; 20: 165.

[134] Wang Y, Zeng J, Chen W, Fan J, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Novel Oncogene in Liver Cancer. Noncoding RNA. 2023; 9: 19.

[135] Wang Y, Yang F, Peng Q, Mei K, He H, Yang Q. Long non-coding RNA SNHG1 activates glycolysis to promote hepatocellular cancer progression through the miR-326/PKM2 axis. J Gene Med. 2022; 24: e3440.

[136] Zhang C, Wang H, Liu Q, Dai S, Tian G, Wei X, et al. LncRNA CCAT1 facilitates the progression of gastric cancer via PTBP1-mediated glycolysis enhancement. J Exp Clin Cancer Res. 2023; 42: 246.

[137] Zhou Y, Huang Y, Hu K, Zhang Z, Yang J, Wang Z. HIF1A activates the transcription of lncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p. Cell Death Dis. 2020; 11: 176.

[138] Ma Y, Sun W, Zhang Q, Gao B, Cai W, Liu Q, et al. lncRNA BSG-AS1 is hypoxia-responsive and promotes hepatocellular carcinoma by enhancing BSG mRNA stability. Biochem Biophys Res Commun. 2021; 566: 101-7.

[139] Xu Y, Liu Y, Li Z, Li H, Li X, Yan L, et al. Long noncoding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR675. Oncol Rep. 2020; 44: 165-73.

[140] Jasim SA, Majeed AA, Uinarni H, Alshuhri M, Alzahrani AA, Ibrahim AA, et al. Long non-coding RNA (lncRNA) PVT1 in drug resistance of cancers: Focus on pathological mechanisms. Pathol Res Pract. 2024; 254: 155119.

[141] Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007; 132: 330-42.

[142] Deng Z, Hou J, Xu H, Lei Z, Li Z, Zhu H, et al. The Prognostic Value of a lncRNA Risk Model Consists of 9 m6A Regulator-Related lncRNAs in Hepatocellular Carcinoma (HCC). Evol Bioinform Online. 2023; 19: 11769343221142013.

[143] Huang Y, Xiang B, Liu Y, Wang Y, Kan H. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett. 2018; 437: 56-66.

[144] Quan G, Ren B, Xu J, Zhou J, Wu G, Li Q, et al. Effect and Mechanism of LncRNA HOTAIR on Migration, Apoptosis and Proliferation of Hepatocellular Carcinoma Cells. J Biomater Tissue Eng. 2022; 12: 461-70.

[145] Davodabadi F, Mirinejad S, Malik S, Dhasmana A, Ulucan-Karnak F, Sargazi S, et al. Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer. Nanoscale. 2024; 16: 3881-914.

[146] Vanli S, Kurtoglu F, Alan BS, Akcakavak G, Ozdemir O. Investigation of the effects of Theranekron and Sorafenib treatments on carcinogenesis, apoptosis and biochemical profile in hepatocellular carcinoma in rats. Toxicol Mech Methods. 2024; 34: 750-60.

[147] Vanlı S, Kurtoğlu F, Suvarıklı Alan B, Akçakavak G, Özdemir Ö. Evaluation of The Effects of Tarantula Cubensis Alcohol Extract and Sorafenib Treatments on P21 Protein, Total Antioxidant Capacity and Metabolic Profile in Experimental Rats Hepatocellular Carcinoma. Manas J Agric Vet Life Sci. 2024; 14: 201-9.

[148] Dinleyici G, Kurtoglu F, Alan BS, Vanli S, Akcakavak G, Ozdemir O. Evaluation of the effects of Theranekron and Sorafenib treatments on alpha-fetoprotein, heat shock protein 90 alpha and indoleamine 2,3 dioxygenase 1 enzyme levels in experimental hepatocellular carcinoma in rats. Mol Biol Rep. 2025; 53: 14.

[149] Karasu N, Kuzucu M, Mat OC, Gul M, Yay A, Dundar M. Protective effect of deinoxanthin in sorafenib-induced nephrotoxicity in rats with the hepatocellular carcinoma model. Naunyn Schmiedebergs Arch Pharmacol. 2025; 398: 5969-88.

[150] Bahriz HA, Abdelaziz RR, El-Kashef DH. Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway. Toxicol Appl Pharmacol. 2025; 495: 117202.

[151] Zhao L, Si K, Luo S, Zhang L, Mao S, Zhang W. Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025; 44: 200.

[152] Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E, Nevo Y, et al. Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. Cancer Res. 2017; 77: 1155-67.

[153] Beylerli O, Gareev I, Sufianov A, Ilyasova T, Guang Y. Long noncoding RNAs as promising biomarkers in cancer. Noncoding RNA Res. 2022; 7: 66-70.

[154] Kim HS, Yoon JH, Baek GO, Yoon MG, Han JE, Cho HJ, et al. Tumor Endothelial Cells-Associated Integrin Alpha-6 as a Promising Biomarker for Early Detection and Prognosis of Hepatocellular Carcinoma. Cancers (Basel). 2023; 15: 4156.

[155] Kim SS, Baek GO, Son JA, Ahn HR, Yoon MK, Cho HJ, et al. Early detection of hepatocellular carcinoma via liquid biopsy: panel of small extracellular vesicle-derived long noncoding RNAs identified as markers. Mol Oncol. 2021; 15: 2715-31.

[156] Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, Park JG, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer. 2019; 144: 1444-52.

[157] Yuan S, Yang F, Yang Y, Tao Q, Zhang J, Huang G, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patientsʼ poor recurrence-free survival after hepatectomy. Hepatology. 2012; 56: 2231-41.

[158] Zeng Z, Dong J, Li Y, Dong Z, Liu Z, Huang J, et al. The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2019; 47: 3067-71.

[159] Abdelmoety AA, Elhassafy MY, Said RSO, Elsheaita A, Mahmoud MM. The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study. Clin Exp Hepatol. 2023; 9: 129-37.

[160] Yuan W, Sun Y, Liu L, Zhou B, Wang S, Gu D. Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma. Cell Physiol Biochem. 2017; 44: 125-32.

[161] Yin Q, Huang X, Yang Q, Lin S, Song Q, Fan W, et al. LncRNA model predicts liver cancer drug resistance and validate in vitro experiments. Front Cell Dev Biol. 2023; 11: 1174183.

[162] Guerriero P, Moshiri F, Lupini L, Sabbioni S, Negrini M, Callegari E. Circulating tumor DNAs and non-coding RNAs as potential biomarkers for hepatocellular carcinoma diagnosis, prognosis and response to therapy. Hepatoma Res. 2019; 5: 6.

[163] Abbastabar M, Sarfi M, Golestani A, Khalili E. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. EXCLI J. 2018; 17: 900-13.

[164] Zhang M, Zheng Y, Sun Y, Li S, Chen L, Jin X, et al. Knockdown of NEAT1 induces tolerogenic phenotype in dendritic cells by inhibiting activation of NLRP3 inflammasome. Theranostics. 2019; 9: 3425-42.

[165] Cha H, Kim M, Ahn N, Jeong SD, Ignatova E, Chi SW, et al. Role of UPF1 in lncRNA-HEIH regulation for hepatocellular carcinoma therapy. Exp Mol Med. 2024; 56: 344-54.

[166] Lai M, Yang Z, Zhou L, Zhu Q, Xie H, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012; 29: 1810-6.

[167] Sun L, Su Y, Liu X, Xu M, Chen X, Zhu Y, et al. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. J Cancer. 2018; 9: 2631- 9.

[168] Elsherbeny ME, Elsergany AR, Shaker OG. Association of lncRNA MEG3 Rs7158663 Polymorphism and Serum Expression with Colorectal Cancer in Egyptian Patients. Rep Biochem Mol Biol. 2023; 12: 102-11.

[169] Yao J, Fu J, Liu Y, Qu W, Wang G, Yan Z. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p. Ann Hepatol. 2021; 23: 100297.

[170] Wang J, Zhang Y, Lian W, Gan M. Long Non-Coding RNA PVT1 Facilitates Radiation-Induced Vascular Endothelial Cell Injury through Sponging MicroRNA-9-5p. Radiat Res. 2024; 202: 670-6.

[171] Wang X, Liu H, Shi L, Yu X, Gu Y, Sun X. LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation. Cell Cycle. 2018; 17: 439-47.

[172] Lou Z, Xu K, Qiao L, Su X, Ou-Yang Y, Miao L, et al. Diagnostic Potential of the Serum lncRNAs HOTAIR, BRM and ICR for Hepatocellular Carcinoma. Front Biosci (Landmark Ed). 2022; 27: 264.

[173] Sha Z, Zhang P. LncRNA-GAS5 and its Promoter Region Polymorphism Associate with Helper Th17 Polarization and Predict Postoperative Pain and the Prognosis of the Patients with Hepatocellular Carcinoma Undergoing Hepatectomy. Iran J Immunol. 2022; 19: 349-57.

[174] Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15: 599-616.

[175] Zhou C, Yang F, Yuan S, Ma J, Liu F, Yuan J, et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology. 2016; 63: 850- 63.

[176] Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017; 16: 167-79.

[177] Javanbakht H, Mueller H, Walther J, Zhou X, Lopez A, Pattupara T, et al. Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. Mol Ther Nucleic Acids. 2018; 11: 441-54.

[178] Amit D, Hochberg A. Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. Int J Clin Exp Med. 2012; 5: 296-305.

[179] Chang L, Wang G, Jia T, Zhang L, Li Y, Han Y, et al. Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget. 2016; 7: 23988-4004.

[180] Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of Long Noncoding RNAs. Annu Rev Immunol. 2017; 35: 177-98.

[181] Ren Y, Li RQ, Cai YR, Xia T, Yang M, Xu FJ. Effective Codelivery of lncRNA and pDNA by Pullulan-Based Nanovectors for Promising Therapy of Hepatocellular Carcinoma. Adv Funct Mater. 2016; 26: 7314-25.

[182] Hurd PJ, Nelson CJ. Advantages of next-generation sequencing versus the microarray in epigenetic research. Brief Funct Genomic Proteomic. 2009; 8: 174-83.

[183] Ma S, Zhou M, Xu Y, Gu X, Zou M, Abudushalamu G, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023; 22: 7.

[184] Li Y, Ye J, Xu S, Wang J. Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC. Discov Oncol. 2023; 14: 142.

[185] Cabús L, Lagarde J, Curado J, Lizano E, Pérez-Boza J. Current challenges and best practices for cell-free long RNA biomarker discovery. Biomark Res. 2022; 10: 62.

[186] Wang G, Lee-Yow Y, Chang HY. Approaches to probe and perturb long noncoding RNA functions in diseases. Curr Opin Genet Dev. 2024; 85: 102158.

[187] Daghistani H, Hegazy GA, Alkhalofah M, Alsobeihy A, Nasser S, Gad H, et al. Long noncoding RNAs in familial hypercholesterolemia: biomarkers, therapeutics, and AI in precision medicine. Lipids Health Dis. 2025; 24: 182.

[188] Hostiuc M, Scafa A, Iancu B, Iancu D, Isailă O, Ion OM, et al. Ethical implications of developing RNA-based therapies for cardiovascular disorders. Front Bioeng Biotechnol. 2024; 12: 1370403.

[189] Hosseini SA, Haddadi MH, Fathizadeh H, Nemati F, Aznaveh HM, Taraj F, et al. Long non-coding RNAs and gastric cancer: An update of potential biomarkers and therapeutic applications. Biomed Pharmacother. 2023; 163: 114407.